Neurobo Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Phase 1 clinical trial timelines significantly accelerated top-line data readout from single ascending dose part 1 now expected in the third quarter of 2024 first patient dosed in the multiple ascending dose part 2 expected in the third quarter of 2024 cambridge, mass. , april 17, 2024 /prnewswire/ -- neurobo pharmaceuticals, inc. (nasdaq: nrbo), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the single ascending dose (sad) part 1 of its two-part phase 1 clinical trial of da-1726, a novel, dual oxyntomodulin (oxm) analog agonist that functions as a glucagon-like peptide-1 receptor (glp1r) and glucagon receptor (gcgr), for the treatment of obesity.

Full data readout expected in the second half of 2024 cambridge, mass. , april 1, 2024  /prnewswire/ -- neurobo pharmaceuticals, inc. (nasdaq: nrbo), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of part 1 of its two-part, phase 2a clinical trial evaluating the efficacy and safety, of da-1241, a novel g-protein-coupled receptor 119 (gpr119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (mash).

Received first site institutional review board (irb) approval  to proceed with the phase 1 trial of da-1726 in obesity phase 1 trial of da-1726 expected to dose first patient in second quarter of 2024 received safety review committee (src) approval recommending that the two-part phase 2a trial of da-1241 for the treatment of mash continue without modification data from the phase 2a trial of da-1241 expected in the second half of 2024 cash of $22.4 million, expected to fund the company into the fourth quarter of 2024 cambridge, mass. , march 28, 2024 /prnewswire/ --  neurobo pharmaceuticals, inc. (nasdaq: nrbo), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended december 31, 2023 and provided a corporate strategic update.

Blinded safety review completed for the first 6 months of the phase 2a clinical trial conduct; recommending trial continue without modification full data readout expected in the second half of 2024 cambridge, mass. , march 13, 2024 /prnewswire/ -- neurobo pharmaceuticals, inc. (nasdaq: nrbo), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced receipt of safety review committee (src) approval, recommending that the two-part phase 2a trial of da-1241, a novel g-protein-coupled receptor 119 (gpr119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (mash), continue without modification following a blinded safety review of the first six months of study conduct.

Cambridge, mass., march 4, 2024 /prnewswire/ -- neurobo pharmaceuticals, inc. (nasdaq: nrbo), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases of cardiometabolic diseases, today announced the appointment of marshall woodworth as chief financial officer, principal financial officer and principal accounting officer, effective march 1, 2024, following his tenure as acting chief financial officer since october 27, 2023.

CAMBRIDGE, Mass. , Feb. 12, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H.

Last week, the Federal Reserve's interest rate decision and the latest non-farm payroll (NFP) data dictated the stock market's performance. During heightened volatility, a handful of stocks stood out due to intense price momentum, which may continue into the coming week due to company-specific events.

CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following industry and investor conferences in January: January 4-6: NASH-TAG Conference 2024.

BOSTON , Dec. 1, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.  (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, Marshall H. Woodworth, Acting Chief Financial Officer and Robert Homolka, Senior Vice President of Clinical Operations, will present a company overview, including updates on the company's promising cardiometabolic assets, DA-1241, in development as a treatment for NASH and DA-1726, in development for the treatment of obesity, at the following investor conferences in December: December 7: Investor Summit Virtual Conference.

BOSTON , Oct. 17, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, and Robert Homolka, Senior Vice-President of Clinical Operations, will present a company overview at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24 th at 2:30 pm ET.

Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.

We pick three medical stocks - MOH, RDY and NRBO - that have gained more than 5% in the past three months amid market volatility.

Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.

Have you ever dreamt of uncovering a hidden gem in the stock market, something that could turn your modest investment into a jackpot? Welcome to the world of penny stocks.

NeuroBo Pharmaceuticals, Inc. (NRBO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.